NCT02564393

Completed

Induction of Neutrophilic Traps ( NETs ) by the Environment ...

University Hospital, Tours Source

Compare

Other study identifiers

Sponsor study identifier

PHAO09-PD / MucoNETs

Study Type

observational

Actual enrollment (reported)

55

Locations

1 country

Sites

1

Timeline

Study Start

May 2011

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

May 2013

Actual (reported)

Study Completion

Not reported

Date not reported

Brief Summary

The study is defined in 3 stages of in vitro assays : Phase 1 : Secretion of NETs in response to lung disease and their secretion of factors. This is a transversal study in which we compare :

Producing NETs (DNA and proteases ) by neutrophils purified from sputum and blood of patients
Producing NETs (DNA and proteases ) by purified neutrophils in the blood of patients and blood of control subjects Phase 2: Mechanisms of activation of NETs secretory pathways . This phase will identify receptors (TLR ) involved in the secretion of NETs and analyze the involvement of dependent transduction pathways calcium and PKC . It will be performed on control blood neutrophils. Phase 3: Analysis of cell death ( NETose ) This is a transversal study that will analyze : the mode of cell death of neutrophils purified blood and sputum of patients and control blood neutrophils by flow cytometry and transmission electron microscopy .

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 55 participants
Study completion date: Not reported
Date not reported
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
May 2011
Date type not reported
This date has not been verified as actual or estimated.
Primary Completion
May 2013
Actual (reported)
First Submitted
September 29, 2015
Actual (reported)
First Posted
September 30, 2015
Actual (reported)

Last Updated: September 30, 2015
Status Verified: September 2015
Last Update Submitted: September 29, 2015

Conditions

Cystic Fibrosis

Outcome Measures

Primary Outcomes (1)

the DNA concentration secreted into the extracellular environment neutrophil activated
1 hour

Study Arms (2)

T

Control

A

Adult with cystic fibrosis

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Pathophysiological study comparing a " Cystic fibrosis " group to a control group (adults)

You may qualify if:

Patients :

Sponsors & Collaborators

University Hospital, Tours
Otherlead

Study Sites (1)

CHRU de Tours

Tours, France

MeSH Terms

Conditions

Cystic Fibrosis

Condition Hierarchy (Ancestors)

Pancreatic DiseasesDigestive System DiseasesLung DiseasesRespiratory Tract DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesInfant, Newborn, Diseases

Enrollment

55 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE CONTROL
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

September 29, 2015

First Posted

September 30, 2015

Study Start

May 2011

Date type not reported

This date has not been verified as actual or estimated.

NCT02994017

Prognostic Value of Functional Exercise Test (EFX) in Cystic Fibrosis

Not ApplicableCompleted

NCT01605565

Functional Analysis by Dynamic Imaging of the Respiratory Epithelium in Infants With Cystic Fibrosis

Not ApplicableCompleted

NCT01537614

Pharmacokinetic Study of Aerosolized Colimycin in Cystic Fibrosis

Phase 1Completed

NCT01915875

Impact of Global Care of the Pain at Chronic Painful Patients Affected by Cystic Fibrosis

Not ApplicableCompleted

NCT01837589

Quantitative Computed Tomodensitometry in Patients With Cystic Fibrosis

Not ApplicableCompleted

NCT04970225

Cystic Fibrosis Blood Neutrophils

Not ApplicableCompleted

Men or women over 18

Patients with mucoviscidose in stable condition, i.e. not having presented an acute push of bronchopulmonary attack requiring a antibiothérapie or a hospitalization for treatment of its disease during the 2 previous weeks

Signed consent

Volunteers :

Men or women over 18

Without respiratory antecedent nor known respiratory pathology

Signed consent

You may not qualify if:

Patients :
Volunteers :

Contact the study team to confirm eligibility.

Primary Completion

May 2013

Actual (reported)

Last Updated

September 30, 2015

Record last verified: 2015-09

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT02564393
Data provider: ClinicalTrials.gov
Source updated: 2015-09-30
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:37:26 UTC

Locations

FR(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

T

A

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations